{"id":3742,"date":"2021-09-21T23:57:20","date_gmt":"2021-09-21T23:57:20","guid":{"rendered":"https:\/\/skymountmed.com\/?p=3742"},"modified":"2023-12-19T15:52:42","modified_gmt":"2023-12-19T15:52:42","slug":"ai-derived-inhibinol-leads-the-way-for-next-generation-of-consumer-health-products","status":"publish","type":"post","link":"https:\/\/skymountmed.com\/2021\/09\/21\/ai-derived-inhibinol-leads-the-way-for-next-generation-of-consumer-health-products\/","title":{"rendered":"AI-Derived Inhibinol\u2122 Leads the Way for Next Generation of Consumer Health Products"},"content":{"rendered":"

PRNewswire Article<\/a><\/p>\n

CALGARY, AB<\/span>. and\u00a0BATON ROUGE, La.<\/span>,\u00a0Sept. 21, 2021<\/span>\u00a0\/PRNewswire\/ — At a time when global health and dietary challenges require rapid cutting-edge technologies and innovation to improve well-being, Skymount Medical, using research developed at\u00a0Louisiana State University<\/span>\u00a0(LSU<\/span>), announces the launch of Inhibinol\u2122<\/b>\u00a0– a dietary supplement formulated with the help of artificial intelligence (AI) to support the immune system, critical antioxidant functions, and overall cardiovascular health. Interest in dietary supplements for improved health has been growing rapidly.\u00a0According to recent research<\/a><\/u>, the global market for such products is expected to hit a record value of\u00a0306.8B<\/span> by 2026.<\/p>\n

“The pandemic has created a lot of uncertainty surrounding immune system health,” said Chris Galliano, Chief Technology Officer of Skymount Medical. “AI-derived Inhibinol\u2122<\/b>\u00a0is the first product of its kind, and a prime example of a smarter generation of dietary supplements, which we hope will empower people to take charge of and have more confidence in, their own health and wellness. In essence, you can think of Inhibinol\u2122\u00a0<\/b>as a personal health shield.”<\/p>\n

Inhibinol\u2122<\/b>\u00a0was designed to be a highly effective blend of natural extracts, essential vitamins and minerals. The platform used to discover and develop Inhibinol\u2122<\/b> is called DeepDrug\u2122. By leveraging AI, DeepDrug\u2122 can score and correlate millions of molecular combinations at a speed unattainable through\u00a0traditional research methods.<\/p>\n

The DeepDrug\u2122 formulations are resulting in novel products, such as Inhibinol\u2122, intended to help correct the vitamin\/mineral imbalance in the body. Inhibinol\u2122 also relies on familiar ingredients, such as ginseng and chamomile, to fight free radicals, which can negatively impact cellular function and overall immune health.<\/p>\n

The LSU<\/span>\u00a0research team that created DeepDrug\u2122 in 2012 is led by\u00a0Supratik Mukhopadhyay<\/span>, associate professor in the LSU Department of Computer Science and an expert on health applications of AI. To date, his discoveries have been awarded three U.S. patents, with at least four more currently pending.<\/p>\n

“As researchers, we are proud of our growing partnership with Skymount,” Mukhopadhyay said. “This is a great example of how companies and universities can work together to develop critical solutions and new products to benefit people all around the world.”<\/p>\n

Now available in the U.S., Inhibinol\u2122 can be purchased online at www.inhibinol.com<\/a><\/u>. Retail partners will be announced in the coming months.<\/p>\n

About Inhibinol\u2122<\/b><\/p>\n

Inhibinol\u2122, a product of Skymount Medical Holding Company U.S. Inc, is a patent-pending novel nutraceutical formulation that was created using DeepDrug\u2122<\/b>– an AI technology platform, licensed from Skymount Medical’s research partner\u00a0Louisiana State University<\/span>.<\/p>\n

Skymount Medical’s mission is to be completely transparent with consumers in identifying the most effective nutraceuticals to improve and maintain health and wellness, and to accelerate the rapid discovery of better nutraceuticals and medicines through AI. To learn more about Inhibinol\u2122, visit www.inhibinol.com<\/a><\/u>. To learn more about Skymount Medical, visit\u00a0www.skymountmed.com<\/a><\/u>.<\/p>\n

SOURCE Inhibinol<\/p>\n","protected":false},"excerpt":{"rendered":"

PRNewswire Article CALGARY, AB. and\u00a0BATON ROUGE, La.,\u00a0Sept. 21, 2021\u00a0\/PRNewswire\/ — At a time when global health and dietary challenges require rapid cutting-edge technologies and innovation to improve well-being, Skymount Medical, using research developed at\u00a0Louisiana State University\u00a0(LSU), announces the launch of … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/posts\/3742"}],"collection":[{"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/comments?post=3742"}],"version-history":[{"count":1,"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/posts\/3742\/revisions"}],"predecessor-version":[{"id":4065,"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/posts\/3742\/revisions\/4065"}],"wp:attachment":[{"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/media?parent=3742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/categories?post=3742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/skymountmed.com\/wp-json\/wp\/v2\/tags?post=3742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}